About Us M&S Decisions provides model-based solutions to support development of new drugs for pharmaceutical companies READ MORE Services M&S Decisions services include population PKPD and quantitative systems pharmacology READ MORE Research M&S Decisions does research in systems biology, immunology, clinical pharmacology, cell dynamics READ MORE News See the info on the latest conferences, collaborations and activities! READ MORE

Optimize your Research and Development with M&S Decisions

Our mission is to develop Drug-Disease modeling platforms to be used as quantitative tools, in support of decision-making across R&D continuum. It’s important to apply such platforms of quantitative knowledge integration towards real projects. Thus it allows to address recurring questions on compound selection, dose & dose scheduling, therapeutic window, biomarker selection, patient populations and selection, combination therapies and study design optimization.

Kirill Peskov, CEO / Кирилл Песков, Генеральный директор ООО «Эм энд Эс десижанс»

Kirill Peskov,
Chief Executive Officer

About M&S Decisions

M&S Decisions is a scientific consulting company, founded in May 2015. We use modeling and simulation techniques to support decision making in drug development.

We have expertise in translational science, quantitative systems pharmacology, population modeling, biostatistics and post-marketing research.

We provide and share our experience across the Skolkovo Biomedical cluster building the strong partnership with scientific startups and society.

in M&S Decisions team
scientific articles
given at conferences

Our Team

Our team has been working together for more than 5 years and consists of 15 modeling scientists with core scientific expertise in systems pharmacology, pharmacometrics, model-based drug development, data mining and meta-analysis.

M&S Decisions Team / Сотрудники компании ООО «Эм энд Эс десижанс»

Our experience

Pharmacometrics 100%
Systems Pharmacology 85%
Biostatistics and Data Science 77%
Biology and Pharmacology 69%
Drug Discovery 54%
Physics and Mathematics 46%
Software development 38%

Our Partners


Get more information on our scientific engagement!

We are actively building engagement and impact with the federal and local health authorities through a scientific dialogue and based on quantitative pharmacometrics.